Donald Hooker
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
87
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Donald Hooker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TDOC Teladoc Health | Maintains: Overweight | $180 → $100 | $9.21 | +985.78% | 18 | Feb 23, 2022 | |
| CRL Charles River Laboratories International | Maintains: Overweight | $450 → $390 | $180.96 | +115.52% | 5 | Feb 17, 2022 | |
| DGX Quest Diagnostics | Maintains: Overweight | $168 → $170 | $155.29 | +9.47% | 4 | Dec 13, 2021 | |
| IQV IQVIA Holdings | Maintains: Overweight | $270 → $290 | $209.16 | +38.65% | 4 | Nov 17, 2021 | |
| PHR Phreesia | Maintains: Overweight | $70 → $73 | $18.47 | +295.24% | 8 | Jul 12, 2021 | |
| RXRX Recursion Pharmaceuticals | Initiates: Overweight | $36 | $6.40 | +462.50% | 1 | May 11, 2021 | |
| AMWL American Well | Initiates: Sector Weight | n/a | $9.00 | - | 1 | Apr 16, 2021 | |
| VEEV Veeva Systems | Maintains: Overweight | $332 → $353 | $212.78 | +65.90% | 2 | Feb 17, 2021 | |
| RCM R1 RCM | Maintains: Overweight | $24 → $26 | $14.26 | +82.33% | 5 | Jan 6, 2021 | |
| HQY HealthEquity | Downgrades: Sector Weight | n/a | $86.33 | - | 11 | Dec 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $84 | $86.96 | -3.40% | 2 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $23.46 | - | 8 | Jul 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $212 → $170 | $227.10 | -25.14% | 7 | Mar 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $220.40 | - | 6 | Sep 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $68 → $46 | $1.75 | +2,536.10% | 2 | Nov 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $20.28 | - | 1 | Oct 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $319.56 | - | 2 | Jul 10, 2017 |
Teladoc Health
Feb 23, 2022
Maintains: Overweight
Price Target: $180 → $100
Current: $9.21
Upside: +985.78%
Charles River Laboratories International
Feb 17, 2022
Maintains: Overweight
Price Target: $450 → $390
Current: $180.96
Upside: +115.52%
Quest Diagnostics
Dec 13, 2021
Maintains: Overweight
Price Target: $168 → $170
Current: $155.29
Upside: +9.47%
IQVIA Holdings
Nov 17, 2021
Maintains: Overweight
Price Target: $270 → $290
Current: $209.16
Upside: +38.65%
Phreesia
Jul 12, 2021
Maintains: Overweight
Price Target: $70 → $73
Current: $18.47
Upside: +295.24%
Recursion Pharmaceuticals
May 11, 2021
Initiates: Overweight
Price Target: $36
Current: $6.40
Upside: +462.50%
American Well
Apr 16, 2021
Initiates: Sector Weight
Price Target: n/a
Current: $9.00
Upside: -
Veeva Systems
Feb 17, 2021
Maintains: Overweight
Price Target: $332 → $353
Current: $212.78
Upside: +65.90%
R1 RCM
Jan 6, 2021
Maintains: Overweight
Price Target: $24 → $26
Current: $14.26
Upside: +82.33%
HealthEquity
Dec 2, 2020
Downgrades: Sector Weight
Price Target: n/a
Current: $86.33
Upside: -
Aug 7, 2020
Maintains: Overweight
Price Target: $80 → $84
Current: $86.96
Upside: -3.40%
Jul 6, 2020
Downgrades: Sector Weight
Price Target: n/a
Current: $23.46
Upside: -
Mar 30, 2020
Maintains: Overweight
Price Target: $212 → $170
Current: $227.10
Upside: -25.14%
Sep 23, 2019
Downgrades: Sector Weight
Price Target: n/a
Current: $220.40
Upside: -
Nov 13, 2017
Maintains: Overweight
Price Target: $68 → $46
Current: $1.75
Upside: +2,536.10%
Oct 24, 2017
Downgrades: Sector Weight
Price Target: n/a
Current: $20.28
Upside: -
Jul 10, 2017
Downgrades: Sector Weight
Price Target: n/a
Current: $319.56
Upside: -